Ocular adnexal metastases from renal cell carcinoma: An update and comprehensive literature review

Tejal Magan1, Tejus Pradeep1, Madalina Tuluc2, Jurij R. Bilyk3, Tatyana Milman1,2

Abstract:

PURPOSE: The purpose of this study was to review the clinical presentation, systemic work-up, and outcomes of all previously reported ocular adnexal (OA) metastases from renal cell carcinoma (RCC).

METHODS: This was a literature review. PubMed and Google Scholar databases were searched for all well-documented cases of OA metastases from RCC.

RESULTS: Final analysis identified 44 patients with either biopsy-confirmed (41/44, 93%) or treatment response-documented (3/44, 6%) OA metastases from RCC. Thirty-four (77%) patients were male. The median age was 60 years (mean: 60, range: 22–87 years). The most common presenting signs were proptosis (10/44, 23%) and adjacent extraconal fat, extending from the sinonasal tract in 7/10 (70%) of these cases. OA metastases were initial manifestation of RCC in 18/44 (41%) patients. At the time of primary tumor diagnosis, 22 of 30 (73%) patients had American Joint Committee on Cancer Stage IV disease with metastases to 2 or more sites in 13 (57%) patients. Seventeen of 42 (40%) patients underwent local therapy only, which most commonly included excision/enuxeration with margin control (10/17, 59%). Twenty-five of 42 (60%) patients had systemic therapy, which included biologic agents and chemotherapy. The absolute 5-year survival rate was 66% with significantly improved survival in patients reported after 2006 (92% vs. 42%, P = 0.04) and in those with isolated OA metastases (100% vs. 27%, P = 0.02) at 30 months.

CONCLUSION: Although RCC metastases to OA occur in a setting of advanced disease, the recent advances in diagnostic modalities and targeted therapies resulted in improved survival.

Keywords:
Ocular adnexal metastases, ocular renal cell carcinoma, renal cell carcinoma eye, renal cell carcinoma ocular adnexal, renal cell carcinoma orbit

Introduction

Renal cell carcinoma (RCC) is one of the most common cancers affecting both sexes in the United States.[1] According to the Review of the Surveillance, Epidemiology, and End Results (SEER) cancer registry, the overall incidence and mortality rates of RCC in the United States have steadily increased between 1992 and 2015.[2] The rise in RCC incidence has been attributed to an increase in the prevalence of RCC risk factors, such as smoking, obesity, and hypertension,[1,4] and to the higher rate of incidental detection of RCC driven by the increasing availability of the imaging studies. In recent years, however, the incidence rates of RCC have stabilized, and the mortality rates have decreased.[2] It is speculated that this decline in mortality is related to earlier detection and improved therapies for metastatic RCC.[2]

Approximately one-third of patients with RCC have metastatic disease at the time of diagnosis, with lung, bones, liver, and brain being the most commonly affected.[5,6] Ocular adnexal (OA) and intraocular involvement by RCC is infrequent.[7] To our knowledge, the most recent largest published systematic review by Shome et al. in 2008 included 33 patients with OA RCC metastases.[1] In light of changes in the...
With the advancement in epidemiology and treatment approaches to RCC over the last 15 years,

we provide an updated comprehensive review of the published literature on the RCC metastatic to the OA to characterize its clinical presentation, systemic manifestations, diagnosis, and management.

**Methods**

Institutional review board approval was waived for this literature review. This study adhered to the ethical principles outlined in the Declaration of Helsinki as amended in 2013 and was Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.

**Literature search**

A comprehensive review of the literature was performed with a systematic search of the PubMed and Google Scholar databases for all articles published between January 1957 and January 2021 using the following key terms: “renal cell carcinoma ocular adnexal metastases” or “renal cell carcinoma orbital metastases” or “orbital metastases kidney” or “renal cell carcinoma sinonasal metastases” or “renal cell carcinoma lacrimal gland metastases” or “renal cell carcinoma ocular muscle metastases” or “renal cell carcinoma eyelid” or “renal cell carcinoma conjunctival metastases” or “renal cell carcinoma eye” or “renal cell carcinoma ocular adnexa” or “renal cell carcinoma orbit” or “renal cell carcinoma sinonasal” or “renal cell carcinoma lacrimal gland” or “renal cell carcinoma ocular muscle” or “renal cell carcinoma eyelid” or “renal cell carcinoma conjunctiva.” Additional articles were found by reference searching. Duplicates were removed. All articles published in all languages that met the eligibility criteria were selected for further analysis.

**Eligibility criteria**

To be included for detailed analysis, only peer-reviewed case studies and case series were included that documented OA (conjunctiva, eyelid, orbital fat, extraocular muscle, lacrimal gland, and orbital bone) biopsy-confirmed metastases from RCC. If an OA biopsy was not performed, documentation of response to systemic therapy for metastatic RCC was required for inclusion in this study. Isolated intraocular RCC metastases were excluded.

**Data collection**

All articles that met the inclusion criteria were reviewed for the following data: patient demographics (age at diagnosis of OA metastases, sex, and ethnicity), presenting ocular symptoms, eye laterality, duration of symptoms, distribution of OA involvement by metastasis, history of RCC, histopathological type of RCC, presence of other synchronous metastases, American Joint Committee on Cancer (AJCC) tumor-node-metastasis system staging at the time of RCC diagnosis, diagnostic modalities, management of OA and systemic disease, ophthalmic and systemic outcomes, and follow-up period.

**Statistical analysis**

All analysis was performed using RStudio Desktop 1.2.5033 (RStudio Inc., Boston, MA, USA). Significance testing was performed on Kaplan–Meier survival distributions using the log-rank test. \( P \leq 0.05 \) was considered statistically significant.

**Results**

**Patient demographics and presenting features**

Review of the literature identified 44 patients\[8,13-51\] who met the inclusion criteria for this study. Table 1 summarizes the demographics and presenting characteristics. Patients with OA metastases from RCC presented at an average age of 60 years (median: 60, range: 22–87). Thirty-four (77%) patients presented with OA metastases from RCC.

**Table 1: Ocular adnexal metastases from renal cell carcinoma: Demographics and presenting characteristics**

| Variables                          | n (%) |
|------------------------------------|-------|
| Age (years)                        |       |
| Mean                               | 60    |
| Median                             | 60    |
| Range                              | 22-87 |
| Sex                                |       |
| Male                               | 34/44 (77) |
| Female                             | 10/44 (23) |
| Ethnicity                          |       |
| Caucasian                          | 8/12 (67) |
| African American                   | 1/12 (8) |
| Hispanic                           | 1/12 (8) |
| Asian                              | 1/12 (8) |
| Other                              | 1/12 (8) |
| Presenting ocular symptoms         |       |
| Proptosis                           | 19/44 (43) |
| Mass                               | 14/44 (32) |
| Diplopia                           | 12/44 (27) |
| Pain/discomfort                    | 8/44 (18) |
| Vision change                      | 8/44 (18) |
| Swelling/chemosis                  | 4/44 (9) |
| Other                              | 16/44 (36) |
| Laterality                         |       |
| Right eye                          | 22/44 (50) |
| Left eye                           | 19/44 (43) |
| Bilateral                          | 3/44 (7) |
| Tissue primarily involved          |       |
| Conjunctiva                        | 8/44 (18) |
| Orbital space not otherwise specified | 7/44 (16) |
| Muscle                             | 6/44 (14) |
| Orbital bone*                      | 10/44 (23) |
| Intracanal orbital fat             | 3/44 (7) |
| Extraocular orbital fat            | 3/44 (7) |
| Lacrimal gland                     | 1/44 (2) |
| OA focality                        |       |
| Unifocal                           | 33/40 (83) |
| Multifocal                         | 7/40 (18) |
| History of RCC at the time of diagnosis |       |
| Yes                                | 26/44 (59) |
| No                                 | 18/44 (41) |

*Epistaxis, nasal obstruction/congestion, redness, photophobia, epiphora, ptosis, headache, *In 7 patients, orbital involvement occurred as a result of extension from the sinonasal tract. RCC: Renal cell carcinoma, OA: Ocular adnexal.

[Downloaded free from http://www.saudijophthalmol.org on Monday, May 23, 2022, IP: 147.140.233.15]
patients were male. Of the 12 patients with documented ethnicity, most were Caucasian (8/12, 67%). The most common presenting ocular symptoms were proptosis (19/44, 43%), an OA mass (14/44, 32%), and diplopia (12/44, 27%). The average duration of ocular symptoms was 3 months (median: 3, range: 0.3–8). In most patients, the OA metastases were unilateral (41/44, 93%) and unifocal (33/40, 83%). Most OA metastases were centered in the orbital bone with extension into the adjacent orbital fat, accounting for 10 of 44 (23%) cases. Bony orbital involvement generally occurred as a result of extension of metastasis from the sinonasal tract in 7 of these 10 (70%) patients. Other frequently involved OA tissues were conjunctiva (8/44, 18%), muscle (6/44, 14%), intraconal orbital fat (3/44, 7%), extraconal orbital fat (3/44, 7%), lacrimal gland (1/44, 2%), or orbital space not otherwise specified (7/44, 16%).

**Imaging**

The detailed information on diagnostic work-up is documented in Table 2. Orbital imaging was performed in 34 of 44 (77%) patients. The most common diagnostic study for evaluation of orbital disease was computed tomography (CT) scan (17/34, 50%). Multimodal imaging was performed in 10 of 34 (29%) patients, which included a combination of plain X-ray, ultrasound, CT/CT angiography (CTA), and magnetic resonance imaging (MRI). CT of the abdomen was the most common systemic imaging study performed (15/24, 63%) followed by multimodal imaging (5/24, 21%), which included a combination of plain X-ray/pyelogram, ultrasound, CT/CTA, or MRI.

**Pathologic diagnosis and histopathologic characteristics of renal cell carcinoma**

OA biopsy documenting metastatic RCC was performed in 41 of 44 (93%) patients, which was incisional in 26/41 (63%) and excisional in 15/41 (37%) [Table 2]. Three of 41 (7%) patients were empirically diagnosed with metastatic OA RCC based on clinical and imaging findings and had a documented response to systemic therapy for metastatic RCC. Ancillary immunohistochemical studies on tissue were performed in 18/25 (72%) cases and included cytokeratins (6/25, 24%), CD10 (8/25, 32%), vimentin (7/25, 28%), epithelial membrane antigen (EMA) (3/25, 12%), carbonic anhydrase IX (CAIX) (2/25, 8%), paired-box gene 8 (PAX8) (2/25, 8%), and RCC antigen (RCC) (1/25, 4%). In 14 patients with documented pathology data on primary RCC, the diagnosis was established by incisional biopsy in 5/14 (36%) and by nephrectomy in 9/14 (64%). Of 22 patients with available information, the most common RCC type was clear cell (18/22, 82%), followed by papillary (2/22, 9%) and medullary (2/22, 9%) [Table 3].

**Systemic disease characteristics**

Table 3 summarizes the systemic characteristics of RCC. The AJCC 8th edition staging system for kidney tumors

### Table 2: Ocular adnexal metastases from renal cell carcinoma: Diagnostic work-up

| Variables | n (%) |
|-----------|-------|
| OA metastasis work-up | |
| OA biopsy | |
| Incisional/fine-needle aspiration* | 26/41 (63) |
| Excisional | 15/41 (37) |
| Ancillary studies on biopsied tissue | |
| Immunohistochemical stains** | 18/25 (72) |
| None | 7/25 (28) |
| Orbital imaging | |
| CT | 17/34 (50) |
| Multimodal† | 10/34 (29) |
| MRI | 3/34 (9) |
| X-ray | 2/34 (6) |
| Ultrasound | 2/34 (6) |
| Systemic work-up | |
| RCC biopsy, primary site | |
| Incisional biopsy | 5/14 (36) |
| Nephrectomy | 9/14 (64) |
| Systemic imaging | |
| CT | 15/24 (63) |
| Multimodal† | 5/24 (21) |
| Other† | 3/24 (13) |
| MRI | 1/24 (4) |

*Immunohistochemical stains including positive for any of the following: CD10, vimentin, cytokeratin (CK7/18/20), CAM 5.2, AE1/AE3, EMA, Ki67, CAIX, PAX8, CD34, CD68, bh11, CEA, anti-AFP, smarcb1/ini1, cyclin D1, RCC antigen, †Combination of imaging with plain X-ray, CT/CT angiogram, MRI or ultrasound, †Combination of imaging with CT/CT angiogram, MRI or ultrasound, §Pyelogram. RCC: Renal cell carcinoma, OA: Ocular adnexal, CT: Computed tomography, MRI: Magnetic resonance imaging, CEA: Carcinoembryonic antigen, AFP: Alpha-fetoprotein, EMA: Epithelial membrane antigen, CAIX: Carbonic anhydrase IX, PAX8: Paired-box gene 8, CK8: cytokeratin 8

### Table 3: Ocular adnexal metastases from renal cell carcinoma: Systemic disease characteristics

| Variable | n (%) |
|----------|-------|
| Type of renal cell carcinoma | |
| Clear cell | 18/22 (82) |
| Papillary | 2/22 (9) |
| Medullary | 2/22 (9) |
| AJCC staging at the time of primary tumor diagnosis* | |
| Stage I (T1, N0, M0) | 3/30 (10) |
| Stage II (T2, N0, M0) | 2/30 (7) |
| Stage III (T1/T2/T3, N1, M0) or (T3, N0, M0) | 3/30 (10) |
| Stage IV (T4, any N, M0) or (any T, any N, M1) | 22/30 (73) |
| Time (months) to ocular metastases from diagnosis or nephrectomy of RCC | |
| Mean, median, range | 79.5 (78, 1-180) |
| Other synchronous metastases sites | |
| Multifocal† | 13/23 (57) |
| Lung | 5/23 (22) |
| Adrenal gland | 1/23 (4) |
| Vertebrae | 1/23 (4) |
| Pelvic bones | 1/23 (4) |
| Mediastinum | 1/23 (4) |
| Other‡ | 1/23 (4) |

*RCC TNM staging, AJCC 8th edition. †Two or more sites from brain, adrenal gland, lung, vertebrae, pelvic bones, mediastinum, liver, skin, breast, diaphragm, oral cavity. ‡Perihilar region. RCC: Renal cell carcinoma, AJCC: American Joint Committee on Cancer, TNM: Tumor-node-metastasis
was used to record the stage at the time of diagnosis of the primary tumor. Most patients (22/30, 73%) had Stage IV (any T, any N, M1) disease at the time of diagnosis, presenting with distant metastasis [Table 3]. OA metastases presented following detection of primary RCC in 26/44 (59%) and were initial manifestation of RCC in 18/44 (41%) patients [Table 1]. The average time from diagnosis of primary RCC to OA metastases was 80 months (median: 78, range: 1–180) [Table 3]. OA was the only metastatic site in 8 of 31 (26%) patients who had documented systemic evaluation data. Concurrent extra-OA metastases were identified in 23 on 31 (74%) patients, which most commonly involved lung (5/23, 22%) and were multifocal (two or more sites) in 13/23 (57%) patients [Table 3].

Management

Table 4 summarizes the management and outcomes of patients with OA metastasis from RCC. Information on management of OA RCC metastases was available on 42 of 44 (95%) patients. Of patients with OA metastases who underwent local therapy only (17/42, 40%), the most common intervention was resection with margin control in 10/17 (59%) patients and biopsy or resection followed by radiotherapy to the orbit in 6/17 (35%) patients. Two patients with a locally advanced disease involving sinuses and skull base underwent orbital exenteration, either as a monotherapy (reported in 2012) or followed by radiotherapy (reported in 1957). Twenty-five of 42 (60%) patients had systemic treatment in addition to any local OA therapy, which included biologic agents only (11/42, 26%), chemotherapy only (3/42, 7%), radiotherapy only (1/42, 2%), surgical resection of extra-OA metastases (1/42, 2%), palliative therapy (1/42, 2%), and combination therapy in 8 out of 42 (19%). The combination therapy included radiotherapy with surgery (2/8, 25%), chemotherapy with biologic agents (2/8, 25%), radiotherapy with biologic agents (2/8, 25%), chemotherapy with radiotherapy and biologic agents (1/8, 13%), and chemotherapy with radiosurgery (1/8, 13%). Treatment of primary RCC included nephrectomy in 30/33 (91%) with neoadjuvant biologic agents in 2/33 (6%) and surgery with radiotherapy in 1/33 (3%). Two patients (2/33, 6%) refused treatment. Biologic agents used included receptor protein-tyrosine kinase inhibitors (sunitinib, sorafenib, and pazopanib) and immunomodulatory agents (immune checkpoint inhibitors, interferon-alpha, and interleukin-2).

Outcome

The average follow-up was 18 months (median: 12, range: 0.3–72 months) [Table 4]. Of the 37 patients with available follow-up, 10/37 (27%) were alive with no evidence of disease, 18/37 (49%) alive with disease, 8/37 (22%) deceased due to disease, and 1/37 (3%) deceased due to another cause. The overall 5-year Kaplan–Meier survival rate for 27 patients with available information was 66% [Figure 1]. A subgroup analysis of 22 patients with complete information on OA RCC metastasis reported between 2006 and 2020 (15/22, 68%) demonstrated a significantly improved survival at 30-month mark when compared to those reported between 1990 and 2005 (92% vs. 42% vs. P =0.04) [Figure 2]. In addition, in a subgroup analysis of 21 patients with complete information, patients who presented with metastases to OA only (8/21, 38%) versus those who had metastases to additional sites (13/21,
immunohistochemical studies are frequently performed to support the morphologic diagnosis. Clear cell RCC expresses PAX8, CD10, CAIX, RCC, epithelial markers (cytokeratins AE1/AE3 and CAM5.2 and EMA), and vimentin [Figure 5b-d]. Thus, this immunohistochemical panel is frequently used in evaluation of suspected metastatic RCC.

OA involvement by RCC occurs on average 6–7 years following the diagnosis of primary tumor in 59% of patients. However, metastases as late as 15 years following the diagnosis of primary RCC can occur, highlighting the importance of careful medical and surgical history. Importantly, our review demonstrated that OA RCC can also occur as an initial manifestation of metastatic disease in 41% of patients. Thus, RCC should be an important consideration in a patient with orbital metastasis from an unknown primary, prompting appropriate systemic evaluation. Systemic imaging such as CT, positron emission tomography/CT, MRI, and ultrasound are useful screening modalities for RCC with multimodal imaging employed in 21% of patients in this review.

Approximately 15%–30% of patients with RCC have metastases at the time of diagnosis and 20%–50% will progress to metastatic cancer with distant metastases most
This improvement in survival has been noted a significantly improved 5-year survival of patients with metastatic RCC, including those with previously known metastatic disease or as an initial manifestation of RCC. Because OA metastases from RCC present in a setting of advanced disease, systemic therapy plays an important role and was employed in 57% of patients in this review. Biologic therapy has become increasingly important in management of RCC, evolving from nontargeted immune-based therapies, such as interferon-alpha and interleukin-2 in the 1990s to targeted therapies, such as receptor protein-tyrosine kinase inhibitors from 2006 and on, and immune checkpoint inhibitor therapies in recent years. This trend is also seen in our review of reports from 2006, which documented the use of mammalian target of rapamycin inhibitors, checkpoint inhibitors, and receptor tyrosine kinase inhibitors.

Survival for RCC is highly dependent on the stage at diagnosis, with only 10%–12% 5-year survival for Stage IV metastatic disease documented in prior studies. However, the recent SEER database review found that mortality rate for metastatic RCC decreased significantly since 2012. This improvement in survival has been attributed to the more rigorous imaging guidelines to detect RCC and the use of novel immunotherapy and targeted therapy agents. In our review for OA RCC metastases, we found that the absolute 5-year survival rate was 66%. Patients with isolated OA RCC metastases had improved survival when compared to those with additional metastases to other sites. In line with the observations from SEER database, we noted a significantly improved 5-year survival in patients who had OA RCC metastases reported in the last 15 years (2006–2020).

**Limitations**

The inherent limitations of this study are the small sample size, which reflects rarity of RCC metastases to OA and heterogeneity in pathology reporting, diagnostic studies, oncologic staging, and therapeutic options, which reflects the evolution in our diagnostic approach, risk stratification, and management of RCC over the course of 5 decades.

**Conclusion**

OA metastasis from RCC can occur as an initial manifestation of RCC in 41% of patients. In patients with previously diagnosed RCC, OA metastases tend to occur in a setting of previously known metastatic disease on average 6–7 years after diagnosis and as late as 15 years following diagnosis. Advances in diagnostic modalities and targeted therapies over the last 15 years have allowed significant improvement in survival of patients with metastatic RCC, including those with OA metastasis.

**Financial support and sponsorship**
Tejal Magan, M.D., received funding from the Théa Pharmaceuticals Educational Award Scheme, UK, and from The Spectacle Makers’ Education Trust for Ophthalmologists in Training, Apothecaries’ Hall, Black Friars Lane, London, EC4V 6EL, UK, to undertake this research.

Conflicts of interest
There are no conflicts of interest.

References
1. Cheng L, Zhang S, MacLennan GT, Lopez-Beltran A, Montironi R. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol 2009;40:10-29.
2. Saad AM, Gad MM, AL-Husseini MJ, Ruhan IA, Sonbol MB, Ho TH. Trends in renal-cell carcinoma incidence and mortality in the united states in the last 2 decades: A SEER-based study. Clin Genitourin Cancer 2019;17:46-57.e5.
3. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010;7:245-57.
4. Kabaria R, Klaassen Z, Terris MK. Renal cell carcinoma: Links and risks. Int J Nephrol Renovasc Dis 2016;9:45-52.
5. Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, et al. Distribution of metastatic sites in renal cell carcinoma: A population-based analysis. Ann Oncol 2012;23:973-80.
6. Ritchie AW, Chisholm GD. The natural history of renal carcinoma. Semin Oncol 1983;10:390-400.
7. Ferry AP, Font RL. Carcinoma metastatic to the eye and orbit. I. A clinicopathologic study of 227 cases. Arch Ophthalmol 1974;92:276-86.
8. Shome D, Honavar SG, Gupta P, Vemuganti GK, Reddy PV. Metastasis to the eye and orbit from renal cell carcinoma – A report of three cases and review of literature. Surv Ophthalmol 2007;52:213-23.
9. Subramanian P, Haas NB. Recent advances in localized RCC. A focus on VEGF and immuno-oncology therapies. Urol Oncol 2018;36:23-30.
10. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal cell carcinoma. N Engl J Med 2017;376:354-66.
11. Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, et al. Ocular adnexal renal cell carcinoma metastases: A SEER-medicare database analysis. Clin Genitourin Cancer 2017;15:e573-82.
12. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017;67:93-9.
13. Van Arnam CE, Fine M. Orbital metastasis of renal carcinoma. AMA Arch Ophthalmol 1957;57:694-701.
14. Woody JH, Geeaerts WJ. Orbital metastasis of renal cell carcinoma. Eye Ear Nose Throat Mon 1966;45:90 passim.
15. Howard GM, Jakobiec FA, Trokel SL, Iwamoto T, Jones IS. Pulsating metastatic tumor of the orbit. Am J Ophthalmol 1978;85:767-71.
16. Kindermann WR, Shields JA, Eiferman RA, Stephens RF, Hirsch SE. Metastatic renal cell carcinoma to the eye and adnexae: A report of three cases and review of the literature. Ophthalmology 1981;88:1347-50.
17. Parrie RE, Goldberg SH, Sassani JW. Renal cell carcinoma metastatic to the orbit: A clinicopathologic report. Ann Ophthalmol 1993;25:100-2.
18. Wolin MJ. Metastatic renal cell carcinoma manifesting as an orbital mass. Am J Ophthalmol 1993;115:542-3.
19. Bersani TA, Costello JJ Jr, Mango CA, Streiten BW. Benign approach to a malignant orbital tumor: Metastatic renal cell carcinoma. Ophthalmic Plast Reconstr Surg 1994;10:42-44.
20. Schmidt M, Schmidt T, Ugi I. Orbital metastasis of kidney carcinoma. Klin Monbl Augenheilkd 1994;205:40-3.
21. Airoldi M, Succo G, Valente G, Cavalot A, Gabriele P, Bumma C. Head and neck metastases of renal cancer after nephrectomy: A report of 2 cases. Tumori 1995;81:213-4.
22. Holt BA, Holmes SA, Kirby RS. Renal cell carcinoma presenting with orbital metastases. Br J Urol 1995;75:246-7.
23. Mezer E, Gdai-On M, Miller B. Orbital metastasis of renal cell carcinoma masquerading as Amaurosis fugax. Eur J Ophthalmol 1997;7:301-4.
24. Ware GT, Haik BG, Morris WR. Renal cell carcinoma with involvement of iris and conjunctiva. Am J Ophthalmol 1999;127:460-1.
25. Watts P, Sullivan S, Davies S, Rao N, Stock D. Electromyography and computed tomography scan-guided fine needle aspiration biopsy of discrete extraocular muscle metastases. J AAPOS 2001;5:333-5.
26. Zdinak LA, Nik NA, Hidayat AA, Hargett NA. Renal medullary carcinoma metastatic to the orbit: A clinicopathologic report. Ophthalmic Plast Reconstr Surg 2004;20:322-5.
27. Hart RH, Luthert PJ, Rose GE. Renal cell carcinoma metastasis masquerading as recurrent orbital haematoma. Orbit 2005;24:281-4.
28. Pompeu AC, Arap S, Silva MN, Monteiro DS. Ocular metastasis as first presentation of renal cell carcinoma: Report of 2 cases. Clinics (Sao Paulo) 2005;60:75-8.
29. Kurlí M, Finger PT, Schneider S, Tena LB. Eyelid-sparing adjuvant radiation therapy for renal cell carcinoma. Ophthalmologica 2006;220:198-200.
30. Tailor R, Inkster C, Hanso I, Shackley DC, Smyth K. Metastatic renal cell carcinoma presenting as a chalazion. Eye (Lond) 2007;21:564-5.
31. Vozmediano-Serrano MT, Toledano-Fernández N, Fdez-Aceñero MJ, Gil-Diez JL, Garcia-Saenz L. Lacrimal sac metastases from renal cell carcinoma. Orbit 2006;25:249-51.
32. Gonçalves AC, Costa PG, Monteiro ML. Inferior rectus muscle metastasis as a presenting sign of renal cell carcinoma: Case report. Arq Bras Oftalmol 2006;69:435-8.
33. Caspar I, Kaskel-Paul S, Herbst E, Höh H. Pseudomalignant conjunctival tumor. Pseudomalignant conjunctival metastases of a clear cell kidney carcinoma. Ophthalmologe 2007;104:250-2.
34. Mudiayensage SY, Prabhattaran VC, Davis GJ, Selva D. Metastatic renal cell carcinoma presenting as a circumscribed orbital mass. Eur J Ophthalmol 2008;18:483-5.
35. Preechawai P, Amrith S, Yip CC, Ghoh KY. Orbital metastasis of renal cell carcinoma masquerading as cysticercosis. Orbit 2008;27:370-3.
36. Rodney AJ, Gombos DS, Fuller GN, Pugliao LC, Tannir NM. Choroidal and conjunctival metastases from renal cell carcinoma. Am J Clin Oncol 2009;32:448-9.
37. Lapp T, Mittelviez H, Werner M, Auw-Härdrich C. Severe bleeding eyelid after trivial trauma: Conjunctival metastasis of a renal cell carcinoma. Graefes Arch Clin Exp Ophthalmol 2012;250:1705-6.
38. Jung JW, Yoon SC, Han DH, Chi M. Metastatic renal cell carcinoma to the orbit and the ethmoid sinus. J Craniofac Surg 2012;23:e136-8.
39. Parida PK. Renal cell carcinoma metastatic to the sinonasal region: Three case reports with a review of the literature. Ear Nose Throat J 2012;91:E11-6.
40. Coloma-González I, Cerioto A, Amezquita-García E, Flores-Preciado J, Salcedo-Casillas G. Orbital pulsatile metastasis as initial presenting sign of metastatic clear cell renal carcinoma. Arch Soc Esp Oftalmol 2014;89:500-3.
41. Gonzalez F, Abalo-Lojo JM, Suarez-Peñaranda JM, Caneiro-Gómez J. Eyelid metastasis as the initial presentation of a renal cell carcinoma. Urology 2015;85:e35-6.
42. Rai R, Jakobiec FA, Fay A. Ocular metastatic renal cell carcinoma presenting with proptosis. Ophthalmic Plast Reconstr Surg 2015;31:e100-8.
43. Kuroki H, Oyama N, Koike H. A case of an orbital metastasectomy in a renal cell carcinoma after sunitinib treatment: A case report. Hinyokika Kiyo 2015;61:335-9.
44. Hainármosi R, Anghelina F, Ionită IG, Zioan OL, Pietrosanu C, Pituju SM, et al. Rare metastasis of renal carcinoma in the frontoethmoid-orbital region – Case report and review of the literature. Rom J Morphol Embryol 2017;58:1497-504.
Magan, et al.: Ocular adnexal renal cell carcinoma metastases

47. Chumdermpadetsuk R, Tooley AA, Godfrey KJ, Krawitz B, Feldstein N, Kazim M. Renal medullary carcinoma with metastasis to the temporal fossa and orbit. Ophthalmic Plast Reconstr Surg 2019;35:e149-51.

48. Heichel J, Siebolts U, Wickenhauser C, Viestenz A. Periocular metastasis as differential diagnosis of pyogenic granuloma and therapeutic marker of a systemic disease. OphthalmoLoge 2019;116:1074-8.

49. Chao AN, Perez-Ordonez B, Hanout M, Rose K, Krema H. Simultaneous choroidal and conjunctival metastases from renal cell carcinoma. Indian J Ophthalmol 2020;68:1652-4.

50. Mahuvakar AD, Nair D, Pai PS. Transnasal endoscopic resection of the intraconal metastases from renal cell carcinoma: A case report and review of literature. Indian J Surg Oncol 2020;11:318-22.

51. Mikail N, Belew D, Ullah A, Payne-Jamaeu Y, Patel N, Kavuri S, et al. Renal cell carcinoma presenting as an isolated eyelid metastasis. J Endourol Case Rep 2020;6:322-4.

52. Civit T, Colnat-Coulbois S, Freppel S. Orbital metastasis. Neurochirurgie 2010;56:148-51.

53. Shields JA, Shields CL, Brotman HK, Carvalho C, Perez N, Eagle RC Jr. Cancer metastatic to the orbit: The 2000 Robert M. Curts Lecture. Ophthalmic Plast Reconstr Surg 2001;17:346-54.

54. Valenzuela AA, Archibald CW, Fleming B, Ong L, O’Donnell B, Crompton JL, et al. Orbital metastasis: Clinical features, management and outcome. Orbit 2009;28:153-9.

55. Magliozzi P, Strianese D, Bonavolontà P, Ferrara M, Ruggiero P, Carandente R, et al. Orbital metastases in Italy. Int J Ophthalmal 2015;8:1018-23.

56. Graves A, Hessamodini H, Wong G, Lim WH. Metastatic renal cell carcinoma: Update on epidemiology, genetics, and therapeutic modalities. ImmuNoTargets Ther 2013;2:73-90.

57. Zhang N, Zhou B, Huang Q, Chen X, Cui S, Huang Z, et al. Multiple metastases of clear-cell renal cell carcinoma to different region of the nasal cavity and paranasal sinus 3 times successively: A case report and literature review. Medicine (Baltimore) 2018;97:e0286.

58. Li Y, Chen P, Chen Z. A population-based study to predict distant metastasis in patients with renal cell carcinoma. Ann Palliat Med 2021;10:4273-88.

59. Bakshi N, Kunju LP, Giordano T, Shah RB. Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: Diagnostic Implications. Appl Immunohistochem Mol Morphol 2007;15:310-5.

60. Butnor KJ, Nicholson AG, Allred DC, Zander DS, Henderson DW, Barrios R, et al. Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch Pathol Lab Med 2006;130:823-7.

61. Sorbellini M, Bratslavsky G. Renal cell carcinoma and prognostic factors predictive of survival. Ann Surg Oncol 2010;17:362-3.

62. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005;173:48-51.

63. Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of renal cell carcinoma. World J Oncol 2020;11:79-87.

64. Hu B, Lara PN Jr., Evans CP. Defining an individualized treatment strategy for metastatic renal cancer. Urol Clin North Am 2012;39:233-49, vii.